Drugs / QN-302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06086522 | Nov 2023 → Dec 2025 overdue | cancer | Qualigen Theraputics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QN-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06086522 ↗ |
| Known as | SOP-1812 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4640542 ↗ |
| Modality | Small molecule | — CHEMBL4640542 ↗ |
| Route | Intravenous | “given once a week, intravenously over 60 min” NCT06086522 ↗ |